HC Wainwright set a $11.00 target price on Cerecor (NASDAQ:CERC) in a report published on Wednesday, TipRanks reports. The brokerage currently has a buy rating on the stock.
Several other research firms have also recently issued reports on CERC. ValuEngine cut shares of Cerecor from a strong-buy rating to a buy rating in a report on Thursday, March 7th. LADENBURG THALM/SH SH reaffirmed a buy rating and issued a $9.00 price target on shares of Cerecor in a report on Thursday, January 17th. TheStreet raised shares of Cerecor from a d rating to a c- rating in a report on Wednesday, January 30th. BidaskClub raised shares of Cerecor from a buy rating to a strong-buy rating in a report on Friday, March 1st. Finally, Maxim Group assumed coverage on shares of Cerecor in a report on Tuesday, April 9th. They set a buy rating and a $10.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Cerecor currently has a consensus rating of Buy and a consensus target price of $10.00.
CERC opened at $5.20 on Wednesday. The firm has a market capitalization of $221.78 million, a P/E ratio of 12.38 and a beta of 2.26. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.79 and a current ratio of 0.84. Cerecor has a 12-month low of $2.71 and a 12-month high of $7.65.
In other Cerecor news, Director Armistice Capital, Llc bought 125,486 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of $5.50 per share, with a total value of $690,173.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Armistice Capital Master Fund bought 374,486 shares of the company’s stock in a transaction on Friday, March 8th. The shares were acquired at an average cost of $5.50 per share, for a total transaction of $2,059,673.00. The disclosure for this purchase can be found here. Insiders have acquired 577,734 shares of company stock worth $3,174,301 over the last three months. 80.20% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the business. Northern Trust Corp raised its holdings in shares of Cerecor by 47.9% during the fourth quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock worth $65,000 after purchasing an additional 6,500 shares during the period. BlackRock Inc. raised its holdings in shares of Cerecor by 18.5% during the fourth quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock worth $109,000 after purchasing an additional 5,293 shares during the period. Virtu Financial LLC acquired a new stake in shares of Cerecor during the first quarter worth $109,000. Tibra Equities Europe Ltd acquired a new stake in shares of Cerecor in the 1st quarter worth about $210,000. Finally, Geode Capital Management LLC increased its holdings in shares of Cerecor by 50.7% in the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock worth $306,000 after acquiring an additional 31,951 shares during the period. 50.26% of the stock is currently owned by institutional investors.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.
Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.